Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cancer Vaccine + CARvac is a preclinical-stage oncology therapeutic being developed by Shanghai BDgene Therapeutics. It utilizes the company's proprietary BD-VLP (virus-like particle) platform to deliver a combined cancer vaccine and CAR-based (Chimeric Antigen Receptor) therapeutic approach, often referred to as a CAR-T cell amplifying vaccine (CARvac). The program is designed to treat solid tumors by enhancing the activity and persistence of CAR-T cells through vaccination. While the specific antigen targets and transgenes have not been publicly disclosed, the therapy leverages the BD-VLP system's ability to deliver mRNA or gene-editing components to modulate the immune response against cancer cells.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cancer Vaccine + CARvac.